| Name
|
Dermorphin
|
| Sequence (Single letter abbreviations)
|
YAFGYPS-NH2
|
| Sequence（Three letter abbreviations）
|
{TYR}{d-ALA}{PHE}{GLY}{TYR}{PRO}{SER}-NH2
|
| C-port
|
NH2
|
| Basic description
|
Dermorphin has no common structure with mammalian opioid peptides. This peptide, isolated from the skin of the South American frog Phyllomedusa sauvagei, is the more selective of all m-opioid agonists.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
802.900
|
| Chemical formula
|
C40H50N8O10
|
| The purity
|
> 95%
|
| Storage conditions
|
Storage at -20°C. Keep tightly closed.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
Ott D, et al. Engineering and functional immobilization of opioid receptors. Protein Eng. Des. Sel. Mar 2005; 18(3): 153-160.
Mollereau C, et al. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. Mar 2005; 67(3): 965-975.
Xia WJ, et al. Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage. Pediatr Res. Oct 2005; 58(4): 784-790.
Guan F., et al. Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping control. Anal Bioanal Chem. 2013 May;405(14):4707 - 17.
|
Dermorphin
